TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34904270

Group type: EXPERIMENTAL
Intervention: Linzagolix 25–200 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35853037

Group type: EXPERIMENTAL
Intervention: Asynchronous telerehabilitation group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Booklet-based rehabilitation group
Number of subjects: 50
Study: 32792163

Group type: EXPERIMENTAL
Intervention: Open transumbilical intussusception reduction (OTIR), n = 27
Number of subjects: 51

Group type: COMPARATOR
Intervention: Laparoscopic reduction (LAP), n = 24
Number of subjects: 51
Study: 34126560

Group type: EXPERIMENTAL
Intervention: UDTM control and FES
Number of subjects: 16

Group type: COMPARATOR
Intervention: FSTM control only
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FES with FSTM control
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UDTM control only
Number of subjects: 16
Study: 32064621

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus β‐D mannuronic acid (M2000)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 34
Study: 36244652

Group type: EXPERIMENTAL
Intervention: High-dose losartan (150 mg/day)
Number of subjects: 3834

Group type: COMPARATOR
Intervention: Low-dose losartan (50 mg/day)
Number of subjects: 3834
Study: 36342424

Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 746

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 746
Study: 32735145

Group type: EXPERIMENTAL
Intervention: 25 mg etanercept
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: 10 mg etanercept
Number of subjects: 550

Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 550
Study: 32169594

Group type: EXPERIMENTAL
Intervention: Vegetable-containing infant foods with fruit
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vegetable-containing infant foods without fruit
Number of subjects: 22
Study: 35718565

Group type: EXPERIMENTAL
Intervention: MOST-Psych (psychological symptoms)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: MOST-DorT (symptoms due to disease or treatment)
Number of subjects: 762
Study: 33480666

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Book listening (control group)
Number of subjects: 78
Study: 34922302

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Sex Therapy (CBST)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Integrated treatment (Sildenafil Citrate + CBST)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 33927121

Group type: EXPERIMENTAL
Intervention: (tissue inhibitor of metalloproteinases‐2)•(insulin‐like growth factor‐binding protein 7) patterns
Number of subjects: 810
Study: 33901062

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia
Number of subjects: 830

Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia
Number of subjects: 830
Study: 32980608

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Hybrid simulation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 32218430

Group type: EXPERIMENTAL
Intervention: EVEN distribution (16.7% at breakfast, 32.8% at lunch, 31.3% at dinner, 19.2% at snacks; N=23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: UNEVEN distribution (15.4% at breakfast, 36.6% at lunch, 34.9% at dinner, 12.4% at snacks; N=24)
Number of subjects: 47
Study: 32185886

Group type: EXPERIMENTAL
Intervention: Bayesian dynamic borrowing designs
Number of subjects: 0
Study: 35276894

Group type: EXPERIMENTAL
Intervention: Higher Protein (HP) diet (1.2 g/kg BW)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lower Carbohydrate (LC) diet (28 en%)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Normal Protein (NP) diet (0.8 g/kg BW)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Normal Carbohydrate (NC) diet (40 en%)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LEDpdr regime
Number of subjects: 121
Study: 32624444

Group type: EXPERIMENTAL
Intervention: Standard diuretic strategy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Carbohydrate antigen 125-guided diuretic strategy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ΔUNa24h (change in urinary sodium at 24 hours)
Number of subjects: 160
Study: 34930967

Group type: EXPERIMENTAL
Intervention: Sleep intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 78
Study: 32300799

Group type: EXPERIMENTAL
Intervention: Probiotics containing Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI for 12 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 35339225

Group type: EXPERIMENTAL
Intervention: Chlorfenapyr LLINs
Number of subjects: 39307

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen LLINs
Number of subjects: 39307

Group type: EXPERIMENTAL
Intervention: Piperonyl butoxide LLINs
Number of subjects: 39307

Group type: COMPARATOR
Intervention: Pyrethroid-only LLINs
Number of subjects: 39307
Study: 34530310

Group type: EXPERIMENTAL
Intervention: Standard walker
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Front‐wheeled walker with straight wheels
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Front‐wheeled walker with caster wheels
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Leg dominance
Number of subjects: 23
Study: 35856208

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine outpatient care
Number of subjects: 200
Study: 34132599

Group type: EXPERIMENTAL
Intervention: RT-PCR test with CbVds-P1/P2 primers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RT-PCR assay with CbVd1-F1/R1 primers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RT-PCR with CbVd1-F1/R1 primers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sequencing of PCR products
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: GenBank deposition
Number of subjects: 27
Study: 35229327

Group type: EXPERIMENTAL
Intervention: Prior knowledge condition (participants know they can take snacks home)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: No prior knowledge condition (participants do not know they can take snacks home)
Number of subjects: 64
Study: 32674229

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐whey protein solution (CHP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 40
Study: 35094006

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no alendronate, received calcifediol and calcium-enriched diet)
Number of subjects: 52
Study: 34340243

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Corticosteroids (CSs)
Number of subjects: 2
Study: 32429839

Group type: EXPERIMENTAL
Intervention: Sevoflurane combined with Remifentanil anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol combined with Remifentanil anesthesia
Number of subjects: 0
Study: 35799658

Group type: EXPERIMENTAL
Intervention: MSBP combined with FBP algorithm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (FBP algorithm only)
Number of subjects: 60
Study: 33586360

Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg on days 1–14 (repeated every 21 days)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 165
Study: 32032229

Group type: EXPERIMENTAL
Intervention: U+D (uphill-downhill training)
Number of subjects: 28

Group type: COMPARATOR
Intervention: H (horizontal training)
Number of subjects: 28

Group type: COMPARATOR
Intervention: C (control group)
Number of subjects: 28
Study: 33875429

Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) 600 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) 1200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 24
Study: 32694367

Group type: EXPERIMENTAL
Intervention: Red blood cells reinfusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline reinfusion (Control)
Number of subjects: 12
Study: 32446170

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Resistance training plus supplementation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Supplementation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study: 34676521

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) combined with standardized post-resuscitation care bundle (PRCB)
Number of subjects: 978

Group type: COMPARATOR
Intervention: Standardized post-resuscitation care bundle (PRCB)
Number of subjects: 978
Study: 32933452

Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE) sessions (six 15-minute sessions) along with physical therapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Physical therapy with PNE
Number of subjects: 7
Study: 35963005

Group type: EXPERIMENTAL
Intervention: Combination therapy (ranibizumab with photodynamic therapy)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Presence of CPREG at month 3
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Absence of polypoidal lesion pulsation on ICGA
Number of subjects: 322
Study: 34339536

Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ambu AuraFlex
Number of subjects: 43
Study: 32505866

Group type: EXPERIMENTAL
Intervention: Instagram
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control (matching game)
Number of subjects: 308
Study: 37822045

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight collagen peptides
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33541288

Group type: EXPERIMENTAL
Intervention: Standard care of treatment & SBRT to all bone metastases
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard care of treatment
Number of subjects: 196
Study: 32773349

Group type: EXPERIMENTAL
Intervention: 3.0-T MRI
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Narrow FOV, standard-resolution CBCT
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (no imaging)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Experimental groups (CBCT and MRI)
Number of subjects: 238
Study: 35875924

Group type: EXPERIMENTAL
Intervention: MHEP (Euphytose®)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 34327227

Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field Treatment (PEMF)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 82
Study: 35730363

Group type: EXPERIMENTAL
Intervention: Panel management intervention using PrEP coordinators and a web-based panel management tool
Number of subjects: 10
Study: 33791385

Group type: EXPERIMENTAL
Intervention: Periocular injection of triamcinolone acetonide (TA) administered once every 3 weeks for a total of 3 times.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Subpalpebral injection of botulinum toxin type A (BTXA) given as a single administration.
Number of subjects: 68
Study: 33994585

Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) and Sequential Organ Failure Assessment (SOFA) score at admission
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (non-critical care group)
Number of subjects: 150
Study: 36239414

Group type: EXPERIMENTAL
Intervention: Psychoanalytic Treatment (PAT)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 227
Study: 34498484

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) for VTE prevention
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Current routine assessment and practice
Number of subjects: 1008
Study: 35978355

Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation therapy consisting of weekly brief behavioural interventions and prescription-free nicotine replacement products (nicotine lozenges, patches, and chewing gum) for 16 weeks (with an option to extend by 8 weeks).
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard care without any added interventions related to smoking cessation.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation therapy.
Number of subjects: 266
Study: 33518321

Group type: COMPARATOR
Intervention: Glycyrrhiza polysaccharide (GCP) 0 mg/kg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Glycyrrhiza polysaccharide (GCP) 200 mg/kg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Glycyrrhiza polysaccharide (GCP) 500 mg/kg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Glycyrrhiza polysaccharide (GCP) 1,000 mg/kg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Glycyrrhiza polysaccharide (GCP) 1,500 mg/kg
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: LPS (1 mg/kg body weight)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Saline (control for LPS)
Number of subjects: 600
Study: 32756138

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 0
Study: 34212181

Group type: EXPERIMENTAL
Intervention: Incentive-based contact investigation
Number of subjects: 3776

Group type: COMPARATOR
Intervention: Household-based contact investigation
Number of subjects: 3776
Study: 34597865

Group type: EXPERIMENTAL
Intervention: Prevent Injury and Enhance Performance (PEP) warm-up
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bicycle ergometer warm-up
Number of subjects: 14
Study: 33371139

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional analgesia
Number of subjects: 100
Study: 33724473

Group type: EXPERIMENTAL
Intervention: Immediate implant placement with simultaneous bone augmentation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed implant placement after ridge preservation
Number of subjects: 40
Study: 33539635

Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagal Nerve Stimulation (t-VNS), 4 hours per day for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagal Nerve Stimulation (t-VNS)
Number of subjects: 20
Study: 36224694

Group type: EXPERIMENTAL
Intervention: Cytology test
Number of subjects: 2967

Group type: EXPERIMENTAL
Intervention: hr-HPV testing
Number of subjects: 2967

Group type: EXPERIMENTAL
Intervention: Combined cervical cytology and hr-HPV test for triage
Number of subjects: 2967

Group type: EXPERIMENTAL
Intervention: Negative baseline hr-HPV
Number of subjects: 2967
Study: 36410472

Group type: EXPERIMENTAL
Intervention: efdamrofusp alfa 2 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: efdamrofusp alfa 4 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: aflibercept 2 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: efdamrofusp alfa 2 mg and 4 mg
Number of subjects: 18
Study: 33139313

Group type: EXPERIMENTAL
Intervention: Opt-out consent process
Number of subjects: 21
Study: 35248683

Group type: EXPERIMENTAL
Intervention: BP + FI
Number of subjects: 249

Group type: COMPARATOR
Intervention: BP
Number of subjects: 249

Group type: COMPARATOR
Intervention: NS
Number of subjects: 249
Study: 33454311

Group type: EXPERIMENTAL
Intervention: Function and Behavior Focused Care for the Cognitively Impaired (FBFC‐CI)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Function and Behavior Focused Care Education (FBFC‐ED)
Number of subjects: 336
Study: 33816765

Group type: EXPERIMENTAL
Intervention: MLC901
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 32498248

Group type: EXPERIMENTAL
Intervention: 100 mg/day ubiquinol (Ubq100)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 150 mg/day ubiquinol (Ubq150)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 60
Study: 35466009

Group type: EXPERIMENTAL
Intervention: 3-point prefabricated orthosis and elastic tape
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cast immobilization
Number of subjects: 70
Study: 33576735

Group type: COMPARATOR
Intervention: lemborexant 10 mg
Number of subjects: 949

Group type: COMPARATOR
Intervention: lemborexant 5 mg
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: lemborexant 5 mg and 10 mg
Number of subjects: 949
Study: 35046055

Group type: EXPERIMENTAL
Intervention: IP cisplatin, IP rintatolimod (dsRNA, TLR3 ligand), oral celecoxib (COX-2 blocker), and IP IFNa at 2, 6, and 18 million units (MU) in cohorts 2, 3, and 4 respectively
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IP cisplatin, IP rintatolimod (dsRNA, TLR3 ligand), oral celecoxib (COX-2 blocker)
Number of subjects: 12
Study: 34546139

Group type: EXPERIMENTAL
Intervention: Healthy Eating Patterns (HEPs)
Number of subjects: 96
Study: 36504629

Group type: EXPERIMENTAL
Intervention: a-tDCS (anodal transcranial direct current stimulation)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: a-tDCS
Number of subjects: 36

Group type: COMPARATOR
Intervention: s-tDCS (sham transcranial direct current stimulation)
Number of subjects: 36
Study: 32805322

Group type: EXPERIMENTAL
Intervention: P–F4 nanoparticles
Number of subjects: 0
Study: 34894781

Group type: EXPERIMENTAL
Intervention: Virtual resilience training
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study: 35646603

Group type: EXPERIMENTAL
Intervention: Internet-based compassion course
Number of subjects: 276

Group type: COMPARATOR
Intervention: Cognitive behavioural stress management course
Number of subjects: 276

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 276
Study: 33020646

Group type: EXPERIMENTAL
Intervention: Continuous dosing of dabrafenib and trametinib
Number of subjects: 206

Group type: COMPARATOR
Intervention: Intermittent dosing of dabrafenib and trametinib
Number of subjects: 206
Study: 33513714

Group type: EXPERIMENTAL
Intervention: Marine protein hydrolysate (MPH) 3 g
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 32675537

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (2 postoperative doses)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo (2 postoperative doses)
Number of subjects: 243
Study: 35397306

Group type: EXPERIMENTAL
Intervention: Myofascial therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Kinesitherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (therapeutic exercise program)
Number of subjects: 44
Study: 32488856

Group type: EXPERIMENTAL
Intervention: Coriandrum sativum extract (300 mg/kg/day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Ischaemia/reperfusion injury (IRI)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Coriandrum sativum extract
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: IRI + Coriandrum sativum
Number of subjects: 4
Study: 34330252

Group type: EXPERIMENTAL
Intervention: Interactive information (narrative condition)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Non-interactive information (narrative condition)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Interactive information (data visualization condition)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Non-interactive information (data visualization condition)
Number of subjects: 180
Study: 32030921

Group type: EXPERIMENTAL
Intervention: 7-day proton pump inhibitor (PPI)-based standard triple therapy (STT; PPI-clarithromycin-amoxicillin)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: 14-day proton pump inhibitor (PPI)-based standard triple therapy (STT; PPI-clarithromycin-amoxicillin)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple therapy (second-line therapy) for 14 days
Number of subjects: 369

Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (second-line therapy) for 7 days
Number of subjects: 369
Study: 35850884

Group type: EXPERIMENTAL
Intervention: Eyebrow suspension with nylon thread (ESN)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Internal browpexy fixation (IBF)
Number of subjects: 27
Study: 33834671

Group type: EXPERIMENTAL
Intervention: Bilateral greater palatine nerve block
Number of subjects: 401
Study: 32417468

Group type: EXPERIMENTAL
Intervention: Doctors/healthcare providers
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Other healthcare-related resources (e.g., CDC, WebMD)
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Parental age increase
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Concussion histories of children
Number of subjects: 1083
Study: 32756053

Group type: EXPERIMENTAL
Intervention: Active waiting (provision of a purpose-built website; n = 20)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Passive waiting (control group; n = 22)
Number of subjects: 42
Study: 34954123

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 33223455

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lidocaine 2% with 1:100,000 epinephrine
Number of subjects: 30
Study: 32074281

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal pessaries 400 mg bid
Number of subjects: 769

Group type: COMPARATOR
Intervention: Progesterone vaginal gel 90 mg od
Number of subjects: 769
Study: 33806511

Group type: EXPERIMENTAL
Intervention: Medium and high density of outdoor tobacco advertising
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Proximity to outdoor tobacco advertising
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Higher density and proximity to outdoor tobacco advertising in poorer neighborhoods
Number of subjects: 400
Study: 33263359

Group type: EXPERIMENTAL
Intervention: office‐based vergence/accommodative therapy with home reinforcement
Number of subjects: 1289

Group type: COMPARATOR
Intervention: base‐in prism reading glasses
Number of subjects: 1289

Group type: COMPARATOR
Intervention: office‐based vergence accommodative therapy
Number of subjects: 1289

Group type: COMPARATOR
Intervention: base‐in prism glasses
Number of subjects: 1289